Antisoma's AS1404 shows slight improvement in ovarian cancer trial

By Elaine Rigoli

Tampa, Fla., June 5 - Antisoma plc announced initial findings from a phase 2 trial of AS1404 (Dmxaa) that randomized patients with recurrent ovarian cancer to receive AS1404 plus chemotherapy or chemotherapy alone.

With initial data available from 62 patients, those receiving AS1404 had a tumor response rate of 61.3%, compared with 54.8% for those receiving chemotherapy alone.

Based in London, Antisoma is a biopharmaceutical company that develops products for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.